Chemoinformaics analysis of 2,4-Dihydroxy-2H-1,4-benzoxazin-3(4H)-one
Molecular Weight | 181.147 | nRot | 0 |
Heavy Atom Molecular Weight | 174.091 | nRig | 12 |
Exact Molecular Weight | 181.038 | nRing | 2 |
Solubility: LogS | -1.097 | nHRing | 1 |
Solubility: LogP | 0.159 | No. of Aliphatic Rings | 1 |
Acid Count | 0 | No. of Aromatic Rings | 1 |
Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
Atoms Count | 20 | No. of Aliphatic Hetero Cycles | 1 |
No. of Heavy Atom | 13 | No. of Aromatic Carbocycles | 1 |
nHetero | 5 | No. of Aromatic Hetero Cycles | 0 |
nBridge Head | 0 | No. Saturated Carbocycles | 0 |
No. of Hydrogen atom | 7 | No. of Saturated Hetero Cycles | 0 |
No. of Carbon atom | 8 | No. of Saturated Rings | 0 |
No. of Nitrogen atom | 1 | No. of Arom Atom | 6 |
No. of Oxygen atom | 4 | No. of Arom Bond | 6 |
nHA | 4 | APOL | 22.3356 |
nHD | 2 | BPOL | 10.1964 |
QED | 0.558 |
Synth | 3.096 |
Natural Product Likeliness | 1.18 |
NR-PPAR-gamma | 0.007 |
Lipinski | Accepted |
Pfizer | Accepted |
GSK | Accepted |
Golden Triangle | Rejected |
Pgp-inh | 0.002 |
Pgp-sub | 0.062 |
HIA | 0.035 |
CACO-2 | -5.255 |
MDCK | 0.0000194 |
BBB | 0.966 |
PPB | 0.102951 |
VDSS | 0.647 |
FU | 0.690561 |
CYP1A2-inh | 0.229 |
CYP1A2-sub | 0.61 |
CYP2c19-inh | 0.042 |
CYP2c19-sub | 0.432 |
CYP2c9-inh | 0.021 |
CYP2c9-sub | 0.879 |
CYP2d6-inh | 0.003 |
CYP2d6-sub | 0.455 |
CYP3a4-inh | 0.008 |
CYP3a4-sub | 0.175 |
CL | 4.344 |
T12 | 0.609 |
hERG | 0.006 |
Ames | 0.773 |
ROA | 0.445 |
SkinSen | 0.509 |
Carcinogencity | 0.698 |
EI | 0.455 |
Respiratory | 0.216 |
NR-Aromatase | 0.617 |
Antiviral | No |
Prediction | 0.875949 |